Abstract
Metastatic colorectal cancer (mCRC) accounts for over 20% of CRC cases and is associated with a poor prognosis. Irinotecan is an important first- and ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
